期刊： DRUGS & AGING, 2022; 39 (9)
Background Psoriasis is a common inflammatory disease in any age group, but also in older patients (>= 65 years of age). Since older patients are o......
期刊： DRUGS & AGING, 2022; 39 (11)
Introduction Pharmaceutical interventions can reduce negative outcomes related to potentially inappropriate prescriptions (PIPs). Objective The object......
期刊： DRUGS & AGING, 2022; 39 (3)
Introduction Benefits and risks of preventive medication change over time for ageing patients and deprescribing of medication may be needed. Deprescri......
期刊： DRUGS & AGING, 2022; 39 (6)
Bladder dysfunction, which involves inadequacies of urine storage or emptying, increases with age. Conventional medications may have insufficient effi......
期刊： DRUGS & AGING, 2022; 39 (3)
Plain Language Summary BPH (enlargement of the prostate gland) compresses the urethra, leading to uncomfortable LUTS such as difficulty starting a uri......
期刊： DRUGS & AGING, 2022; 39 (6)
Depression is one of the most frequent and burdensome non-motor symptoms in Parkinson's disease (PD), across all stages. Even when its severity is mil......
期刊： DRUGS & AGING, 2022; 39 (7)
Antihypertensive drugs are among the most documented regimens worldwide with an overall survival and cardioprotective benefit. However, there is evide......
期刊： DRUGS & AGING, 2022; 39 (1)
Background The Screening Tool of Older Persons' Prescriptions (STOPP)/Screening Tool to Alert to Right Treatment (START) instrument is used to evaluat......
期刊： DRUGS & AGING, 2022; 39 (4)
Background Alzheimer's disease (AD) comprises 60-70% of diagnosed dementia cases, and is characterized by the deposition of beta-amyloid peptide and t......
期刊： DRUGS & AGING, 2022; 39 (8)
Introduction In 2020, the restrictions adopted to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic led to an unpreced......
期刊： DRUGS & AGING, 2022; 39 (8)
Perimenopause marks the transition from a woman's reproductive stage to menopause. Usually occurring between 42 and 52 years of age, it is determined ......
期刊： DRUGS & AGING, 2022; 39 (3)
The risk of having onychomycosis increases with age. Data suggest that the prevalence of onychomycosis may be >= 20% in subjects aged >= 60 year......
期刊： DRUGS & AGING, 2022; 39 (8)
Background Psychotropic medicine utilisation in older adults continues to be of interest because of overuse and concerns surrounding its safety and ef......
期刊： DRUGS & AGING, 2022; 39 (12)
Background Improving or maintaining quality of life (QoL) is an important aim for caring for people with dementia living in residential aged care faci......
